| |
Progenics Stops PRO 206 HCV Entry Inhibitor
|
| |
| |
Progenics stops development of PRO 206; co also announces collaborator has begun clinical testing in Japan of Relistor subcutaneous injection Co announces the discontinuation of development for PRO 206, a pre-clinical compound for the treatment of hepatitis C virus (HCV) infection. The decision was made as part of a portfolio review, and is in line with the co's initiative to allocate resources to the most important programs in order to increase its operating efficiencies. The co will instead focus on its second-generation HCV-entry inhibitor portfolio and anticipates selection of a new development candidate in 2010... Co also announces that its collaborator, Ono Pharmaceutical, has begun clinical testing in Japan of Relistor subcutaneous injection, the first-in-class medicine approved in the US, Canada, the European Union, Australia and Latin American countries for the treatment of opioid-induced constipation.
Preclinical characterization of PRO 206, an orally active HCV ...
Apr 23, 2009 ... Preclinical characterization of PRO 206, an orally active HCV entry inhibitor. Reported by Jules Levin 2009 EASL Annual Meeting ...
www.natap.org/2009/EASL/EASL_87.htm
|
|
| |
| |
|
|
|
